Clinical Infectious Diseases · 2005 · 182 citations · 13 references
MedicinePharmacokineticsPharmacologyMedical GeneticsPharmacogeneticsPharmacogenomicsAntiretroviral TherapyGenotype-phenotype Association AnalysisGenotype-phenotype CorrelationPharmacogenetic TestingPopulation PharmacogeneticsPopulation PharmacogenomicsAntiretroviral PharmacogenomicsCytochrome P450 2B6Cytochrome P450 Genetic PolymorphismCytochrome P450 Genotype EffectsCytochrome P450 GenotypingPharmacogenomics Of Antiretroviral TherapyPharmacogenomics Of Hiv TherapyTherapeutic Dose Range
We examined 516G>T polymorphisms at the gene encoding the cytochrome P450 in 100 human immunodeficiency virus-positive subjects who were receiving efavirenz (EFV). Elevated plasma EFV concentrations were found in 40% of subjects with the polymorphic homozygous genotype and 19% of subjects with the heterozygous genotype. Conversely, 20% of subjects with the wild-type genotype had subtherapeutic concentrations of EFV. CYP2B6-516 genotyping may help to identify subjects who have plasma EFV concentrations that are outside of the therapeutic range.
13
Drug Metabolism and Disposition
Basic & Clinical Pharmacology & Toxicology · 2014 · 2.5K citations
Treatment for Adult HIV Infection
Patrick Yéni, Scott M. Hammer, Martin Hirsch et al. · JAMA · 2004 · 737 citations
Bryan A. Ward, J. Christopher Gorski, David R. Jones et al. · Journal of Pharmacology and Experimental Therapeutics · 2003 · 594 citations